[Primary sclerosing cholangitis].

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and obliteration of intra and/or extrahepatic bile ducts. The disease belongs to the most common cholestatic diseases in adults and at present is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas and those with ulcerative colitis also have an increased incidence of colonic carcinomas. Immunosuppressive treatment is little effective. Ursodeoxycholic acid (UDCA) has been shown to improve liver histology in PSC. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA stenoses of major ducts may develop and early endoscopic dilatation is highly effective. In patients with endstage disease, UDCA is not effective and liver transplantation is indicated.

• Publication year

  2000

• Venue

  Der Internist

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2000/983681PMID 14735241
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

  2002cited by this paper
• Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

  2002cited by this paper
• Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.

  2001cited by this paper
• Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis

  2001cited by this paper
• A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.

  2001cited by this paper
• Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

  2001cited by this paper
• Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis

  2000cited by this paper
• High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

  2000cited by this paper
• Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

  1999cited by this paper
• Recurrence of primary sclerosing cholangitis following liver transplantation

  1999cited by this paper
• Value of brush cytology for dominant strictures in primary sclerosing cholangitis.

  1999cited by this paper
• Influence of Cholestasis on Absorption of Ursodeoxycholic Acid

  1999cited by this paper
• Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation

  1998cited by this paper
• Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography

  1998cited by this paper
• Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers.

  1998cited by this paper
• Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.

  1997cited by this paper
• Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.

  1997cited by this paper
• Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

  1996cited by this paper
• Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation

  1996cited by this paper
• Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential

  1995cited by this paper
• Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.

  1995cited by this paper
• Endoscopic therapy of sclerosing cholangitis

  1995cited by this paper
• Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis.

  1995cited by this paper
• Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.

  1994cited by this paper
• Primary sclerosing cholangitis: refinement and validation of survival models.

  1992cited by this paper
• Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial

  1992cited by this paper
• Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

  1991cited by this paper
• Natural history and prognostic variables in primary sclerosing cholangitis.

  1991cited by this paper
• Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis

  1989cited by this paper
• Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: follow-up assessment of a new therapeutic approach.

  1987cited by this paper
• Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response.

  1987cited by this paper
• Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

  1980cited by this paper

• Lactobacillus plantarum ameliorates intrahepatic cholestasis by modulating the gut microbiota and tryptophan metabolism

  2026cites this paper
• Decoding the Role of H19 in Cholestatic Liver Injury Using snRNA-seq, Spatial Transcriptomics, and Machine Learning-Based Disease Prediction

  2026cites this paper
• Cholestatic biomarkers and symptoms in primary sclerosing cholangitis: a post-hoc analysis of the DILSTENT

  2026cites this paper
• Bile acids as therapeutic agents

  2026cites this paper
• IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury

  2026cites this paper
• Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.

  2026cites this paper
• Systematic Review of Preclinical Evidence on Antifibrotic Potential of Natural Polysaccharides

  2026cites this paper
• Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

  2026cites this paper
• New onset of severe and long-term hepatobiliary diseases post-COVID-19 infection: a systematic review

  2026cites this paper
• FDX1-mediated cuproptosis promotes cholestatic liver injury exacerbated by taurocholic acid-enhanced copper accumulation

  2026cites this paper
• A Closer Look into Autoimmune Liver Diseases

  2025cites this paper
• Exploring shared pathogenic mechanisms and biomarkers in hepatic fibrosis and inflammatory bowel disease through bioinformatics and machine learning

  2025cites this paper
• CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization.

  2025influential citation
• MSP-RON signaling in liver pathobiology and as an emerging therapeutic target: a review of the current evidence

  2025cites this paper
• Mechanisms of biliary stricture and novel therapeutic strategies

  2025cites this paper
• ESGAR consensus statement on MR imaging in primary sclerosing cholangitis

  2025cites this paper
• Protocol for fabricating a vascularized bile duct-on-a-chip

  2025cites this paper
• The 2024 diagnostic criteria for primary sclerosing cholangitis

  2025cites this paper
• All you need to know about the overlap between primary sclerosing cholangitis and inflammatory bowel disease

  2025cites this paper
• Prognostic significance of clinical scoring systems for large‐duct primary sclerosing cholangitis in Japanese patients

  2025cites this paper
• Investigating the Causality and Pathogenesis of Primary Sclerosing Cholangitis in Colorectal Cancer Through Mendelian Randomization and Bioinformatics

  2025cites this paper
• Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility

  2025cites this paper
• Role of the Annexin A protein family in liver diseases: insights and therapeutic opportunities

  2025cites this paper
• Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead

  2025cites this paper
• Risk factors for recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients: A meta-analysis

  2025cites this paper
• Gut Microbiota and Interorgan Communication Among the Gut, Brain, and Beyond

  2025cites this paper
• Causal association between type 1 diabetes and autoimmune cholestasis: A bi-directional Mendelian randomized study

  2025cites this paper
• Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective

  2025cites this paper
• Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus.

  2025cites this paper
• Harnessing Biomaterials for Gene Therapy in Autoimmune Disease

  2025cites this paper
• An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease

  2025cites this paper
• Synergistic effects of ferulic acid and wogonin on cholestatic liver injury via gut microbiota modulation

  2025cites this paper
• Burden of primary sclerosing cholangitis in Sweden (2002–2020): Incidence, outcomes, healthcare utilization, and costs

  2025influential citation
• Rare liver diseases—Etiology, diagnosis and management: A review

  2025influential citation
• Next-Generation Hydrogels for Biliary Organoid Engineering

  2025cites this paper
• Artificial Intelligence-based agents in chronic liver disease: transforming diagnostic and therapeutic workflows through clinical decision-making

  2025cites this paper
• Exploring the biliary microbiome in hepatopancreatobiliary disorders: a comprehensive systematic review of microbial signatures and diagnostic potential

  2025cites this paper
• Actinomycotic Cholecystitis and Pancreatitis: Report of an Unusual Case

  2025cites this paper
• Frequency and Risk Factors of Advanced Neoplasia in Korean Inflammatory Bowel Disease Patients with Low-grade Dysplasia

  2025cites this paper
• A MULTI-MINERAL INTERVENTION TO IMPROVE DISEASE-RELATED AND MECHANISTIC BIOMARKERS IN ULCERATIVE COLITIS PATIENTS

  2025cites this paper
• 24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation

  2025cites this paper
• Development of the natural history component of an early economic model for primary sclerosing cholangitis

  2025cites this paper
• Extensive Nail Changes Are a Possible Clue Indicating Multisystem Involvement in Childhood Langerhans Cell Histiocytosis: A Case Report and Literature Review

  2025cites this paper
• Partial quadrate lobectomy improves early outcomes of laparoscopic Kasai surgery in type III biliary atresia

  2025cites this paper
• Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases

  2025cites this paper
• Shading light in the black box of hepatobiliary imaging

  2025cites this paper
• Harnessing organoid technology to model autoimmune pathways in rheumatological and inflammatory disorders

  2025influential citation
• Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.

  2025cites this paper
• A case of pregnancy complicated by caroli disease

  2025cites this paper
• Gut–Liver Axis, Microbiota, Bile Acids, and Immune Response in Pathogenesis of Primary Sclerosing Cholangitis: An Overview

  2025cites this paper
• Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions

  2025cites this paper
• Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease

  2025cites this paper
• Integrating Etiological Insights With Machine Learning for Precision Diagnosis of Obstructive Jaundice: Findings From a High-Volume Center

  2025cites this paper
• Gamma-glutamyltransferase testing in paediatric inflammatory bowel disease to screen for primary sclerosing cholangitis: a diagnostic study based on routinely collected electronic healthcare data

  2025cites this paper
• Revisiting Tregs in cancer and beyond: immunological control and therapeutic potential

  2025cites this paper
• Accuracy, repeatability, reproducibility and reference ranges of primary sclerosing cholangitis specific biomarkers from quantitative MRCP

  2025cites this paper
• Single and Multiple Doses of Seladelpar Decrease Diurnal Markers of Bile Acid Synthesis in Mice

  2025cites this paper
• Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study

  2025cites this paper
• Clinical Predictors of Polyautoimmunity in Autoimmune Liver Diseases: Insights into Disease Complexity

  2025cites this paper
• Non‐Adherence to Standard Therapy in Autoimmune Hepatitis: Impact of Steroid Use and Over‐the‐Counter Medications

  2025cites this paper
• Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction

  2025cites this paper
• The Significance of Enzymatic Cholestasis in Inflammatory Bowel Disease Patients for the Diagnosis of Primary Sclerosing Cholangitis—A Retrospective Study

  2025cites this paper
• Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study

  2025cites this paper
• Extracellular Matrix Signaling Cues: Biological Functions, Diseases, and Therapeutic Targets

  2025cites this paper
• 68Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma

  2025cites this paper
• Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma

  2025cites this paper
• Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance

  2025cites this paper
• Cultured bacteria isolated from primary sclerosing cholangitis patient bile induce inflammation and cell death

  2025cites this paper
• Primary Sclerosing Cholangitis in a Child: A Rare Case Report

  2025cites this paper
• Integrative multi-omics and causal inference unveil novel therapeutic targets for primary sclerosing cholangitis and its genetic comorbidity with inflammatory bowel disease

  2025influential citation
• Exploring animal models and in vitro models for liver diseases: a review

  2025cites this paper
• From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies

  2025cites this paper
• From Isolation to Information: Launching an Online Community for Patients with Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and Autoimmune Hepatitis in Romania—A Descriptive Study

  2025cites this paper
• Biliary Reconstruction in Liver Transplantation with Primary Sclerosing Cholangitis: Roux-en-Y Hepaticojejunostomy or Duct-to-Duct Anastomosis?

  2025cites this paper
• IL-1 family of cytokines in gastrointestinal and liver disorders

  2025cites this paper
• miR-125a/b as key regulators of the pathogenesis of cholestatic liver diseases: a review of molecular mechanisms

  2025cites this paper
• Immunoregulatory role of miR-155 in cholestatic liver diseases: implications for primary biliary cholangitis and primary sclerosing cholangitis associated with ulcerative colitis

  2025cites this paper
• Hepatocyte Mettl3 Deficiency Drives Primary Sclerosing Cholangitis and Liver Fibrosis via Cholangiocyte‐Macrophage Crosstalk

  2025cites this paper
• Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.

  2025cites this paper
• Gallbladder-derived retinoic acid signalling drives reconstruction of the damaged intrahepatic biliary ducts

  2025cites this paper
• Causal association between autoimmune liver disease and Sjögren's syndrome: A Mendelian randomization study

  2024cites this paper
• Periportal macrophages protect against commensal-driven liver inflammation

  2024cites this paper
• Dominant stricture in paediatric‐onset primary sclerosing cholangitis is associated with impaired prognosis in a long‐term follow‐up

  2024cites this paper
• Challenges and Pitfalls in Pancreatobiliary Cytopathology

  2024cites this paper
• NLRP3 Inflammasome in Acute and Chronic Liver Diseases

  2024cites this paper
• HO-1-induced autophagy establishes a HO-1-p62-Nrf2 positive feedback loop to reduce gut permeability in cholestatic liver disease

  2024cites this paper
• Leveraging pQTL-based Mendelian randomization to identify new treatment prospects for primary biliary cholangitis and primary sclerosing cholangitis

  2024cites this paper
• Autoimmune Liver Disease Associated Uveitis: An Extrahepatic Manifestation or a Polyautoimmunity Phenomenon? Case Reports

  2024cites this paper
• The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study

  2024cites this paper
• Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study

  2024cites this paper
• Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis

  2024cites this paper
• Coexisting Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Overlapping Challenges in Diagnosis and Treatment

  2024influential citation
• Autoimmune Liver Diseases and Rheumatoid Arthritis—Is There an Etiopathogenic Link?

  2024cites this paper
• Fecal microbiota transplantation in autoimmune diseases - An extensive paper on a pathogenetic therapy.

  2024cites this paper
• Pseudo-spectral angle mapping to improve immune cell classification in highly multiplexed fluorescence microscopy images

  2024cites this paper
• Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis

  2024cites this paper
• Liver outcomes following proctocolectomy in patients with primary sclerosing cholangitis and ulcerative colitis

  2024cites this paper
• Spontaneous perforation of the common bile duct: an uncommon complication of primary sclerosing cholangitis

  2024cites this paper
• Setting up an integrated service for PSC-IBD patients: A quality improvement project

  2024cites this paper
• Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity

  2024cites this paper